Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus

Macrophage activation syndrome (MAS) is a rare disease characterised by aberrant immune hyperactivation of T lymphocytes and macrophages driven by cytokine dysfunction. The HLH-2004 protocol is commonly used for the treatment of MAS, but significant toxicities are associated. We describe a case of M...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMJ Case Rep
Päätekijät: Junga, Zachary, Stitt, Rodger, Tracy, Christopher, Keith, Michael
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2017
Aiheet:
Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5624074/
https://ncbi.nlm.nih.gov/pubmed/28827301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-221347
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia